MainStreet Investment Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-14,172
Closed -$4.91M 181
2021
Q2
$4.91M Sell
14,172
-1,301
-8% -$394K 0.42% 70
2021
Q1
$4.33M Sell
15,473
-1,785
-10% -$481K 0.36% 74
2020
Q4
$4.23M Sell
17,258
-2,440
-12% -$629K 0.34% 73
2020
Q3
$5.59M Buy
19,698
+5,798
+42% +$1.62M 0.44% 64
2020
Q2
$3.72M Sell
13,900
-110
-0.8% -$33.1K 0.25% 73
2020
Q1
$4.43M Buy
14,010
+867
+7% +$263K 0.55% 44
2019
Q4
$3.9M Buy
13,143
+824
+7% +$229K 0.43% 60
2019
Q3
$2.87M Sell
12,319
-999
-8% -$233K 0.38% 61
2019
Q2
$3.12M Sell
13,318
-155
-1% -$35.8K 0.41% 60
2019
Q1
$3.18M Buy
13,473
+502
+4% +$158K 0.45% 54
2018
Q4
$3.9M Buy
12,971
+146
+1% +$46.6K 0.6% 45
2018
Q3
$4.53M Sell
12,825
-1,270
-9% -$437K 0.61% 45
2018
Q2
$4.09M Buy
14,095
+1,924
+16% +$541K 0.59% 48
2018
Q1
$3.33M Buy
12,171
+632
+5% +$196K 0.51% 52
2017
Q4
$3.68M Buy
+11,539
New +$3.7M 0.56% 46

Other funds holding BIIB

MainStreet Investment Advisors's BIIB Position: Q3 2021 in Review

MainStreet Investment Advisors sold out of Biogen (BIIB) in Q3 2021, closing a stake of 14,172 shares — an estimated $4.91M sold.

MainStreet Investment Advisors first reported a position in BIIB in Q4 2017 and held it in 15 quarters. The position peaked at $5.59M in Q3 2020. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • MainStreet Investment Advisors reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • MainStreet Investment Advisors sold 14,172 Biogen shares in Q3 2021, an estimated $4.91M.
  • MainStreet Investment Advisors first reported a position in Biogen in Q4 2017 and held it in 15 quarters.
  • MainStreet Investment Advisors's Biogen position peaked at $5.59M in Q3 2020.
  • 1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on MainStreet Investment Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.